MEDIVO2 will improve Sensitivity of the non-invasive diagnosis and prognosis of human brain tumours in vivo. This should facilitate proper therapeutic or surgical care of the patient. For this, we are going to use the detection of the metabolic phenotype of the tumour by single and multivoxel proton magnetic resonance spectroscopy (1H MRS) from 150 additional patients. Diagnostic markers will be automatically extracted by pattern recognition analysis of 1H MRS data. New case classifiers obtained from those markers will be incorporated into the graphical user interface of a Decission Support System (DSS) improved from the present INTERPRET/MEDIVO DSS for display of relevant classification data to clinicians. Furthermore, we will characterize the in vivo metabolomics of tumoral progression in animal models of cancer (brain metastasis of mammary adenocarcinoma in nude mice) and transgenic and knock out mice (astrocytoma and oligodendroglioma) by high field MRS/MRI /7-11.7 T). Finally, a strategy for the biophysical detection of cell proliferation markers in cells and models systems, based in MRS pattern changes in, mostly, the Mobile Lipid MR visible resonances, will be devised. This will be extended to the in vivo situation
|Effective start/end date||13/12/05 → 13/12/08|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.